Published in final edited form as:

Bioorg Med Chem. 2017 December 01; 25(23): 6197–6202. doi:10.1016/j.bmc.2017.06.010.

A Photochemical Flow Reactor for Large Scale Syntheses of Aglain and Rocaglate Natural Product Analogs

Han Yueh, Qiwen Gao, John A. Porco Jr., and Aaron B. Beeler

Department of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, 590 Commonwealth Avenue, Boston, Massachusetts 02215

Abstract

Herein, we report the development of continuous flow photoreactors for large scale ESIPT-mediated [3+2]-photocycloaddition of 2-(*p*-methoxyphenyl)-3-hydroxyflavone and cinnamate-derived dipolarophiles. These reactors can be efficiently numbered up to increase throughput two orders of magnitude greater than the corresponding batch reactions.

Graphical abstract

Keywords

photochemistry; flow chemistry; ESIPT; photocycloaddition; rocaglate; natural product; aglain

1. Introduction

Rocaglates are a class of structurally complex secondary metabolites isolated from plants of the *Aglaia* genus [1-3]. Over 100 rocaglates have been isolated or synthesized, all sharing the cyclopenta[*b*]benzofuran core structure (Figure 1). The naturally occurring family members rocaglamide (**1**), rocaglaol (**2**), silvestrol (**3**), and the synthetic analogue RHT (**4**) possess potent cytotoxicity for a number of cancer cell lines [4-8]. Much of the anticancer activity of these compounds is believed to be derived from translation suppression through inhibition of the RNA helicase eIF4A. However, there have been a number of new and potentially important biological activities reported for the natural products and analogues. Methyl rocaglate (**4**) was found to be a specific inhibitor of TNF α -R or PMA-induced NF- κ B activity in T cell lines [4,5][9-13] and rocaglamide was recently reported to inhibit

Correspondence to: Aaron B. Beeler.

Supporting Information Available: Supplementary data is available in the online version at XXXXX

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

cancer cell migration through Rho GTPase inhibition [14]. In a collaboration with Kramnik and co-workers, we found that the synthetic rocaglate derivatives (**3** and **4**) synergized with low concentrations of IFN γ in primary macrophages to stimulate expression of some IFN-inducible genes, including a key regulatory factor, Irf1, which activates autophagy [15].

It is clear that the rocaglates have a number of unique biological activities that could lead to novel therapeutics. However, the chemical synthesis of rocaglate natural products and analogues has proven highly challenging [16-19]. The common approach leverages an excited-state intramolecular proton transfer (ESIPT)-mediated [3+2]-photocycloaddition to generate aglains (**7**) from 3-hydroxyflavone derivatives (**5**) and dipolarophiles (**6**) which was developed by the Porco laboratory (Scheme 1) [19][20]. Subsequent α -ketol rearrangement and hydroxyl-directed reduction affords the rocaglate skeleton (**8**) [21-25].

While this synthetic approach has been widely utilized, there has remained significant challenges related to practicality and scalability of the photochemical cycloaddition. Thus, synthesis of sufficient material to support medicinal chemistry studies of rocaglate analogues *in vitro* and *in vivo* has been a significant hurdle for development of this class of molecule. Herein, we report a numbering up approach for developing a multigram scale continuous flow reactor for ESIPT [3+2]-photocycloaddition.

2. Results and Discussion

The ESIPT [3+2]-photocycloaddition of 3-hydroxyflavone (**9**) and methyl *trans*-cinnamate (**10**) to obtain aglain (**11**) is typically carried out in batch, but is difficult to scale due to long irradiation times (typically 12 hours), low temperature (0 °C), and high dilution required (30 mM). The typical isolated yield of aglain (**11**) is 40-50% affording on average <150 mg per reaction (Scheme 2a)[21]. In 2012, Tremblay and coworkers reported the use of a recirculating flow reactor for synthesis of methyl rocaglate and related derivatives (Scheme 2c). This three-step sequence (photocycloaddition, α -ketol rearrangement, and hydroxyl-directed reduction) was initiated with 3-hydroxyflavone derivative (**11**) and methyl *trans*-cinnamate and gave an overall 20 % yield of the methyl rocaglate derivative (**13**) on a 3 g scale [26]. The synthesis of *aza*-rocaglates *via* ESIPT [3+2]-photocycloaddition was also recently reported using a recirculating flow device [27] wherein the *aza*-aglaine derivative (**15**) was obtained in 46 % over nine hours of irradiation on a 500 mg scale. However, these methods remain limited in terms of scale and throughput [28]. To enable synthesis and medicinal chemistry programs related to the rocaglate scaffolds and to address the challenges of this reaction, we considered a continuous-flow approach which has been demonstrated to be highly beneficial for large scale synthesis of active pharmaceutical ingredients, natural products, and polymers have been reported [29-32]. In particular, photochemical reactions performed in a continuous-flow can be significantly more efficient than the corresponding batch reactions due to better light penetration, resulting in reduced reaction times, cleaner reactions, and greater scalability [33-39].

2.1 Optimization of ESIPT [3+2]-photocycloaddition in flow

While there have been significant advances in developing flow reactors for large scale photochemical reactions [40-42], there are still few available options which could be applied

to challenging reactions requiring low temperatures and are simple, affordable, and modular. We designed and built a novel flow photoreactor that would enable UV irradiation >300 nm while maintaining a low temperature for the photocycloaddition (Figure 2 A). The reactor utilizes a 150 W metal-halide lamp (>300 nm) which is placed in the center of a reactor containing wrapped FEP tubing. The inner chamber of the reactor is cooled by recirculation of glycol. We built the first flow reactor (Reactor A) using 1/16" OD FEP tubing resulting in 3.5 mL reactor volume.

We began optimization of the reaction using 3-hydroxyflavone **9** [26] and methyl cinnamate **10**. Initial reactions revealed that under typical conditions (30 mM) full conversion was observed with only 15-minute residence time, compared to 9-hour reaction times required for the corresponding batch reaction (Table 1, entries 1 and 2). Increasing the concentration to 60 mM did not affect the reaction and we obtained an increased isolated yield (Table 1, entry 3). In order to maximize the potential throughput and minimize solvent waste, we increased the concentration to 120 mM at which point a longer 30-minute residence time was required for full conversion (Table 1, entry 4). Although isolated yields for the flow reactions were slightly lower than the batch reaction these initial efforts resulted in nearly a 20-fold increase in throughput.

Targeting a key intermediate for medicinal chemistry studies, we evaluated the potential for large-scale synthesis of the Weinreb amide-bearing aglain **17** derived from ESIPT [3+2]-photocycloaddition with hydroxamate **16** [43]. Aglain **17** is the precursor to the rocaglate congener RHT, an important tool molecule for studying inhibition of eIF4A, and an intermediate in the synthesis of many analogues including furan **6**. Photoreaction of 3-hydroxyflavone **9** and **16** afforded 47 % yield after 9 hours irradiation in a batch reactor (Table 1, entry 5) while the flow reaction at 120 mM required 30-minute residence time affording a 36 % isolated yield (Table 1, entry 6).

To increase the throughput of the reaction, we envisioned a numbering up approach [44] wherein we would daisy-chain reactors rather than splitting the reaction stream into separate reactors. In this way, we would effectively increase the total reactor volume allowing for greater flow rate, and subsequent throughput (Figure 2, B and C). We initially combined two reactors (reactor A) which effectively doubled the reactor volume to 7 mL. Reaction of hydroxyflavone **9** and dipolarophile **16** afforded a comparable isolated yield and the reaction throughput was increased from 0.12g/h to 0.22 g/h. Using this system, we synthesized 890 mg of aglain product **17** in only four hours (Table 2, entry 2). By redesigning the reactor to have a larger surface area, it was possible to increase the volume to 6 mL/reactor (reactor B). Using this design, both a single and double reactor afforded similar yield, significantly increasing the throughput to 0.6 g/h (Table 2, entries 3 & 4).

In order to further increase the reactor volume and throughput, we built a new reactor with 1/8" OD FEP, resulting in a total volume of 12.5 mL for each reactor (reactor C). We found that the impact of the longer path length was minimal and we could obtain similar isolated yields with only a slightly longer residence time of 35 minutes. Numbering up this larger reactor to three resulted in a total volume of 37.5 mL, thereby maintaining a 35% yield to realize a throughput of 1.16 g/h (Table 2, entry 5).

A large scale [3+2] photocycloaddition was performed using this latest design. 21.3 g of 3-hydroxyflavone (**9**) and 124.3 g of dipolarophile (**16**) with a total solution volume of 670 mL took 10.5 hours with a flow rate of 1.07 mL/min to reach completion. A total of 12.1 grams of aglain **17** was obtained after purification.

2.2 Synthesis of rocaglate analogs in flow

To validate that this flow system would be generally useful for medicinal chemistry and the synthesis of an array of rocaglate analogues, we evaluated a number of diopolarophiles in the flow ESIPT [3+2]-photocycloaddition. As outlined in Table 43, multiple reaction partners were found to be successful using the system, generally providing moderate to good isolated yields and excellent throughput. With the triple reactor configuration, we observed an increase to 61% isolated yield for methyl cinnamate. Reaction with *p*-bromo ethyl cinnamate (**19**) afforded aglain **24** in 52% isolated yield and the corresponding Weinreb amide (**20**) was equally successful in the reaction (52%). Reaction with *o*-bromo and *m*-bromo Weinreb amides (**21**, **22**) afforded lower isolated yields of the corresponding aglains (**26**: 32% and **27**: 38% respectively) but maintained excellent throughput. The electron rich *p*-methoxy Weinreb amide (**23**) afforded a good yield (47%) and throughput of the expected aglain (**28**).

3. Conclusion

We have developed a series of simple continuous flow photoreactors for carrying out the ESIPT [3+2]-photocycloaddition, generating aglain derivatives on unprecedented scale. We have demonstrated the reactors can be effectively numbered up to increase the reaction throughput without significant change in the overall reaction outcome. Using a triple reactor, we successfully synthesized 12.1 grams of the critical aglain **17** in 10.5 hours. The ability to carry out these challenging reactions on a large scale has significantly improved the prospects for advancing these highly interesting molecules through *in vitro* and *in vivo* medicinal chemistry programs.

4. Experimental

4.1 General information

Photoreactors were constructed with fluorinated ethylene propylene (FEP) tubing (1/16" [OD] – 1/32" [ID], and 1/8" [OD] – 1/16" [ID]). The light source was metal halide lamp (MHL 150 G12) purchased from Ushio America (Cypress, CA) with metal halide ballast (V90D7130K) purchased from Venture Lighting International (Twinsburg, Ohio). Solutions were flowed through the TPFE photoreactors with Harvard Apparatus (Holliston, MA) PHD Ultra syringe pumps or KD Scientific (Holliston, MA) LEGATO 200 syringe pumps.

4.2 General procedure of [3+2]-photocycloaddition

The solvent (70:30 chloroform:2,2,2-trifluoroethanol) for photoreactions was degassed with argon for 10 minutes prior to dissolution of the reaction substrates. A flask containing 3-hydroxyflavone **9** and dipolarophile was evacuated under high vacuum for 30 minutes then charged with argon. The degassed solvent mixture was added to the flask to prepare the

solution in the desired concentration. The solution subsequent reaction solution was transferred to appropriate syringes and placed into the flow system. The crude material was collected and after the reaction was complete the solution was concentrated dry loaded onto Celite followed by chromatography (SiO₂, hexanes/ethyl acetate/Et₃N). From the chromatography column was collected a mixture of the major product with regioisomers and diastereomers still present. Subsequent trituration with ethyl acetate/hexanes solution or recrystallization from acetonitrile afforded pure aglain product as a single diastereomer.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support from Boston University and National Institutes of Health (ABB R33AI105944) is gratefully acknowledged. We thank Dr. Norman Lee (Boston University) for high-resolution mass spectrometry data. NMR (CHE-0619339) and MS (CHE-0443618) facilities at Boston University are supported by the NSF.

References

1. Proksch P, Edrada R, Ebel R, Bohnenstengel FI, Nugroho BW. *Curr Org Chem*. 2001; 5:923–938.
2. Kraus GA, Sy JO. *J Org Chem*. 1989; 54:77–83.
3. Trost BM, Greenspan PD, Yang BV, Saulnier MG. *J Am Chem Soc*. 1990; 112:9022–9024.
4. King ML, Chiang CC, Ling HC, Fugita E, Ochiai M, McPhail AT. *J Chem Soc, Chem Commun*. 1982:1150–1151.
5. Lee SK, Cui B, Mehta RR, Kinghorn AD, Pezzuto JM. *Chem Biol Interact*. 1998; 115:215–228. [PubMed: 9851291]
6. Hwang BY, Su BN, Chai H, Mi Q, Kardono LBS, Afriastini JJ, iswan S, Santarsiero BD, Mesecar AD, Wild R, Fairchild CR, Vite GD, Rose WC, Farnsworth NR, Cordell GA, Pezzuto JM, Swanson SM, Kinghorn AD. *J Org Chem*. 2004; 69:3350–3358. [PubMed: 15132542]
7. Chen W, Pan L, Kinghorn AD, Swanson SM, Burdette JE. *BMC Cancer*. 2016; 16:17. [PubMed: 26762417]
8. Kogure T, Kinghorn AD, Yan I, Bolon B, Lucas DM, Grever MR, Patel T. *Plos One*. 2013; 8:e76136. [PubMed: 24086701]
9. Baumann B, Bohnenstengel F, Siegmund D, Wajant H, Weber C, Herr I, Debatin KM, Proksch P, Wirth T. *J Biol Chem*. 2002; 277:44791–44800. [PubMed: 12237314]
10. Fahrig T, Gerlach I, Horváth E. *Mol Pharmacol*. 2005; 67:1544–1555. [PubMed: 15716464]
11. Rivero-Cruz JF, Chai HB, Kardono LBS, Setyowati FM, Afriatini JJ, Riswan S, Farnsworth NR, Cordell GA, Pezzuto JM, Swanson SM, Kinghorn AD. *J Nat Prod*. 2004; 67:343–347. [PubMed: 15043407]
12. Lee SK, Cui B, Mehta RR, Kinghorn AD, Pezzuto JM. *Chemico-Biol Interact*. 1998; 115:215–228.
13. Pan L, Acuña UM, Li J, Jena N, Ninh TN, Pannell CM, Chai H, Fuchs JR, Carcache de Blanco EJ, Soejarto DD, Kinghorn AD. *J Nat Prod*. 2013; 76:394–404. [PubMed: 23301897]
14. Becker MS, Müller PM, Bajorat J, Schroeder A, Giaisi M, Amin E, Ahmadian MR, Rocks O, Köhler R, Krammer PH, Li-Weber M. *Oncotarget*. 2016; 7:51908–51921. [PubMed: 27340868]
15. Bhattacharya B, Chatterjee S, Devine WG, Kobzik L, Beeler AB, Porco JA Jr, Kramnik I. *Sci Rep*. 6:24409.
16. Kraus GA, Sy JO. *J Org Chem*. 1989; 54:77–83.
17. Davey AE, Taylor RJK. *J Chem Soc, Chem Commun*. 1987:25–27.
18. Davey AE, Schaeffer MJ, Taylor RJK. *J Chem Soc, Chem Commun*. 1991:1137–1139.

19. Dobler MR, Bruce I, Cederbaum F, Cooke NG, Diorazio LJ, Hall RG, Irving E. *Tetrahedron Lett.* 2001; 42:8281–8284.
20. Gerard B, Jones G II, Porco JA Jr. *J Am Chem Soc.* 2004; 126:13620–13621. [PubMed: 15493911]
21. Gerard B, Cencic R, Pelletier J, Porco JA Jr. *Angew Chem Int Ed Engl.* 2007; 46:7831–7834. [PubMed: 17806093]
22. Roche SP, Cencic R, Pelletier J, Porco JA Jr. *Angew Chem Int Ed.* 2010; 49:6533–6538.
23. Rodrigo CM, Cencic R, Roche SP, Pelletier J, Porco JA Jr. *J Med Chem.* 2011;558–562. [PubMed: 22128783]
24. Lajkiewicz NJ, Cognetta AB III, Niphakis MJ, Cravatt BF, Porco JA Jr. *J Am Chem Soc.* 2014; 136:2659–2664. [PubMed: 24447064]
25. Gerard B, Sangji S, O'Leary DJ, Porco JA Jr. *J Am Chem Soc.* 2006; 128:7754–7755. [PubMed: 16771486]
26. Liu T, Nair SJ, Lescarbeau A, Belani J, Peluso S, Conley J, Tillotson B, O'Hearn P, Smith S, Slocum K, West K, Helble J, Douglas M, Bahadoor A, Ali J, McGovern K, Fritz C, Palombella VJ, Wylie A, Castro AC, Tremblay MR. *J Med Chem.* 2012; 55:8859–8878. [PubMed: 23025805]
27. Wang W, Cencic R, Whitesell L, Pelletier J, Porco JA Jr. *Chem Eur J.* 2016; 22:12006–12010. [PubMed: 27338157]
28. Efforts in the synthesis of gram quantities of silvestrol have also been pursued at National Cancer Institute, Developmental Therapeutics Program. <https://dtp.cancer.gov/organization/dscb/smChemistry/silvestrol.htm>
29. Wenger J, Ceylan S, Kirschning A. *Adv Synth Catal.* 2012; 354:17–57.
30. Brzozowski M, O'Brien M, Ley SV, Polyzos A. *Acc Chem Res.* 2015; 48:349–362. [PubMed: 25611216]
31. Porta, r, Benaglia, M., Puglisi, A. *Org Process Res Dev.* 2016; 20:2–25.
32. Junkers T. *Macromol Chem Phys.* 2016; 218:1600421.
33. Knowles JP, Elliott LD, Booker-Milburn KI. *Beilstein J Org Chem.* 2012; 8:2025–2052. [PubMed: 23209538]
34. Gilmore K, Seeberger PH. *Chem Rec.* 2014; 14:410–418. [PubMed: 24890908]
35. Atodiresi I, Vila C, Rueping M. *ACS Catal.* 2015; 5:1972–1985.
36. Tucker JW, Zhang Y, Jamison TF, Stephenson CRJ. *Angew Chem Int Ed.* 2012; 51:4144–4147.
37. Telmesani R, Park SH, Lynch-Colameta T, Beeler AB. *Angew Chem Int Ed.* 2015; 54:11521–11525.
38. Yueh H, Voevodin A, Beeler AB. *J Flow Chem.* 2015; 5:155–159.
39. Cambié D, Bottecchia C, Straathof NJW, Hessel V, Noël T. *Chem Rev.* 2016; 116:10276–10341. [PubMed: 26935706]
40. Elliott LD, Berry M, Harji B, Klauber D, Leonard J, Booker-Milburn KI. *Org Process Res Dev.* 2016; 20:1806–1811.
41. Josland S, Mumtaz S, Oelgemöller M. *Chem Eng Tech.* 2016; 39:81–87.
42. Gutierrez AC, Jamison TF. *J Flow Chem.* 2011; 1:24–27.
43. Nahm S, Weinreb SM. *Tetrahedron Lett.* 1981; 22:3815–3818.
44. Su Y, Kujiipers K, Hessel V, Noël T. *React Chem Eng.* 2016; 1:73–81.

Figure 1. Biologically active rocaglate natural products and analogues

Figure 2.
Flow reactor A.

Double reactor **Triple reactor**

Figure 3.
Daisy-chained reactors.

Scheme 1. ESIPT-mediated [3+2] photocycloaddition

Scheme 2.

Previous studies a) [3+2] photocycloaddition in batch, b) recirculating flow reactor, c) *aza*-aglain synthesis using a recirculating flow reactor.

Scheme 4. Large scale [3+2] –triple reactor C (37.5 mL)

Table 1

Reaction optimization with flow reactor

Entry	[9]	[3+2] Adduct	Residence Time	Flow Rate	Yield
1	30 mM	11	Batch (9 hr)	--	55 %
2	30 mM	11	15 min.	233 μ L/min	32 %
3	60 mM	11	15 min.	233 μ L/min	41 %
4	120 mM	11	30 min.	117 μ L/min	45 %
5	30 mM	17	Batch (9 hr)	--	47 %
6	120 mM	17	30 min.	117 μ L/min	36 %

Table 2

Reaction carried out in the multi-reactor setup

Entry	[9]	Dipolarphile	Reactor Volume	Residence Time	Flow Rate	Yield	Throughput
1	120 mM	16^a	3.5 mL (Single A)	30 min.	117 $\mu\text{L}/\text{min}$	36 %	0.14 g/h
2	120 mM	16^a	7.0 mL (Double A)	30 min.	233 $\mu\text{L}/\text{min}$	29 %	0.22 g/h
3	120 mM	16^b	6.0 mL (Single B)	30 min.	200 $\mu\text{L}/\text{min}$	28 %	0.17 g/h
4	120 mM	16^b	12.0 mL (Double B)	20 min.	600 $\mu\text{L}/\text{min}$	32 %	0.61 g/h
5	120 mM	16^b	37.5 mL (Triple C)	35 min.	1.07 mL/min	35 %	1.16 g/h

Table 3

Reaction with addition reaction partners using triple reactor C.

Entry	[9]	Dipolarophile ^a	[3+2] Adduct	Yield	Throughput
1	120 mM	10	11	61 %	1.92 g/h
2	120 mM	19	24	52 %	1.78 g/h
3	120 mM	20	25	52 %	1.80 g/h
4	120 mM	21	26	32 %	1.10 g/h
5	120 mM	22	27	38 %	1.31 g/h
6	120 mM	23	28	47 %	1.58 g/h

^a 10.0 equiv.